TrialScience translational medicine2019

A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder.

Federico Bolognani et al.PubMed ↗Publisher ↗

No numbers read from the abstract.